The future of breast cancer care is shaped through collaboration, evidence, and continuous scientific exchange — and the 8th Indonesian Issues on Breast Cancer (IIBC 2026) stands as one of Indonesia’s key forums advancing that mission. ✨

Held under the theme “From Global Guidelines to Local Practice: Adapting De-Escalation to Indonesia’s Breast Cancer Management,” IIBC 2026 brought together multidisciplinary healthcare professionals to advance more practical and evidence-based breast cancer care in Indonesia.

At NalaGenetics, together with Strand Life Sciences and Tempus, we showcased integrated precision oncology solutions designed to support better clinical decision-making across the cancer care continuum.

🧬 Strand Life Sciences

• Germline & Somatic Testing for inherited and acquired cancer risk assessment

• CancerSpot for early cancer detection

• Comprehensive Carrier Screening for inherited genetic risk insights

🧬 Tempus

• Liquid Biopsy for minimally invasive genomic profiling

• MRD (Minimal Residual Disease) monitoring for longitudinal cancer management

Through these technologies, we aim to support more precise risk stratification, earlier detection, and dynamic treatment monitoring in oncology care.

Thank you to all healthcare professionals who visited our booth and shared valuable insights throughout the event.

#IIBC2026 #PERABOI #BreastCancer #PrecisionOncology #Genomics #CancerCare #NalaGenetics #StrandLifeSciences #Tempus #HealthcareInnovation #MedicalConference